• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Apollomics Inc. - Warrant (NQ: APLMW )

    0.0100 UNCHANGED
    Streaming Delayed Price Updated: 1:33 PM EDT, Oct 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Apollomics Inc. - Warrant

    < Previous 1 2 Next >
    Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
    Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
    43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with... 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Updated Strategic Focus and Leadership Team Changes
    Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Presentation at the 2024 BIO International Convention
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Private Placement Financing and Addition to Board of Directors
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR... 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
    Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the 2024 Biotech Showcase
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
    From Apollomics Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.